| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:47 UTC |
|---|
| HMDB ID | HMDB0014933 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Sulfasalazine |
|---|
| Description | Sulfasalazine is only found in individuals that have used or taken this drug. It is a drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitro models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown. |
|---|
| Structure | OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1 InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+ |
|---|
| Synonyms | | Value | Source |
|---|
| 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid | ChEBI | | 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid | ChEBI | | 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene | ChEBI | | 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid | ChEBI | | 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid | ChEBI | | 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid | ChEBI | | Azulfidine | ChEBI | | Salazosulfapiridina | ChEBI | | Salazosulfapyridine | ChEBI | | Salazosulfapyridinum | ChEBI | | Salicylazosulfapyridine | ChEBI | | Sulfasalazina | ChEBI | | Sulfasalazinum | ChEBI | | 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoate | Generator | | 2-Hydroxy-5-((4-((2-pyridinylamino)sulphonyl)phenyl)azo)benzoate | Generator | | 2-Hydroxy-5-((4-((2-pyridinylamino)sulphonyl)phenyl)azo)benzoic acid | Generator | | 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoate | Generator | | 2-Hydroxy-5-[4-(pyridin-2-ylsulphamoyl)-phenylazo]-benzoate | Generator | | 2-Hydroxy-5-[4-(pyridin-2-ylsulphamoyl)-phenylazo]-benzoic acid | Generator | | 4-(Pyridyl-2-amidosulphonyl)-3'-carboxy-4'-hydroxyazobenzene | Generator | | 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylate | Generator | | 5-((p-(2-Pyridylsulphamoyl)phenyl)azo)salicylate | Generator | | 5-((p-(2-Pyridylsulphamoyl)phenyl)azo)salicylic acid | Generator | | 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoate | Generator | | 5-(4-(2-Pyridylsulphamoyl)phenylazo)-2-hydroxybenzoate | Generator | | 5-(4-(2-Pyridylsulphamoyl)phenylazo)-2-hydroxybenzoic acid | Generator | | 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylate | Generator | | 5-(p-(2-Pyridylsulphamyl)phenylazo)salicylate | Generator | | 5-(p-(2-Pyridylsulphamyl)phenylazo)salicylic acid | Generator | | Salazosulphapiridina | Generator | | Salazosulphapyridine | Generator | | Salazosulphapyridinum | Generator | | Salicylazosulphapyridine | Generator | | Sulphasalazina | Generator | | Sulphasalazinum | Generator | | Sulphasalazine | Generator | | Sulfasalazin | HMDB |
|
|---|
| Chemical Formula | C18H14N4O5S |
|---|
| Average Molecular Weight | 398.393 |
|---|
| Monoisotopic Molecular Weight | 398.068490268 |
|---|
| IUPAC Name | 2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid |
|---|
| Traditional Name | sulfasalazine |
|---|
| CAS Registry Number | 599-79-1 |
|---|
| SMILES | OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+ |
|---|
| InChI Key | NCEXYHBECQHGNR-QZQOTICOSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a benzene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Azobenzenes |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Azobenzenes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Azobenzene
- Benzenesulfonamide
- Hydroxybenzoic acid
- Salicylic acid or derivatives
- Salicylic acid
- Benzoic acid or derivatives
- Benzoic acid
- Benzenesulfonyl group
- Benzoyl
- 1-hydroxy-2-unsubstituted benzenoid
- Phenol
- Monocyclic benzene moiety
- Pyridine
- Imidolactam
- Benzenoid
- Organosulfonic acid amide
- Heteroaromatic compound
- Vinylogous acid
- Organic sulfonic acid or derivatives
- Organosulfonic acid or derivatives
- Aminosulfonyl compound
- Sulfonyl
- Azo compound
- Azacycle
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 220 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.046 g/L | Not Available | | LogP | 2.5 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 199.7 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.42 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.2239 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.57 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 45.9 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1540.4 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 206.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 93.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 147.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 61.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 325.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 520.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 89.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 688.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 205.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1457.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 255.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 331.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 466.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 160.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 261.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Sulfasalazine,1TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)NC3=CC=CC=N3)C=C2)=CC=C1O | 3835.0 | Semi standard non polar | 33892256 | | Sulfasalazine,1TMS,isomer #2 | C[Si](C)(C)OC1=CC=C(/N=N/C2=CC=C(S(=O)(=O)NC3=CC=CC=N3)C=C2)C=C1C(=O)O | 3893.4 | Semi standard non polar | 33892256 | | Sulfasalazine,1TMS,isomer #3 | C[Si](C)(C)N(C1=CC=CC=N1)S(=O)(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O)=C2)C=C1 | 3724.4 | Semi standard non polar | 33892256 | | Sulfasalazine,2TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)NC3=CC=CC=N3)C=C2)=CC=C1O[Si](C)(C)C | 3830.3 | Semi standard non polar | 33892256 | | Sulfasalazine,2TMS,isomer #2 | C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C)C=C2)=CC=C1O | 3514.6 | Semi standard non polar | 33892256 | | Sulfasalazine,2TMS,isomer #3 | C[Si](C)(C)OC1=CC=C(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C)C=C2)C=C1C(=O)O | 3651.8 | Semi standard non polar | 33892256 | | Sulfasalazine,3TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C)C=C2)=CC=C1O[Si](C)(C)C | 3558.3 | Semi standard non polar | 33892256 | | Sulfasalazine,3TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C)C=C2)=CC=C1O[Si](C)(C)C | 3559.3 | Standard non polar | 33892256 | | Sulfasalazine,3TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C)C=C2)=CC=C1O[Si](C)(C)C | 4698.6 | Standard polar | 33892256 | | Sulfasalazine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)NC3=CC=CC=N3)C=C2)=CC=C1O | 4091.3 | Semi standard non polar | 33892256 | | Sulfasalazine,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC=C(/N=N/C2=CC=C(S(=O)(=O)NC3=CC=CC=N3)C=C2)C=C1C(=O)O | 4199.8 | Semi standard non polar | 33892256 | | Sulfasalazine,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N(C1=CC=CC=N1)S(=O)(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O)=C2)C=C1 | 3998.1 | Semi standard non polar | 33892256 | | Sulfasalazine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)NC3=CC=CC=N3)C=C2)=CC=C1O[Si](C)(C)C(C)(C)C | 4264.7 | Semi standard non polar | 33892256 | | Sulfasalazine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C(C)(C)C)C=C2)=CC=C1O | 3982.9 | Semi standard non polar | 33892256 | | Sulfasalazine,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=CC=C(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C(C)(C)C)C=C2)C=C1C(=O)O | 4103.2 | Semi standard non polar | 33892256 | | Sulfasalazine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C(C)(C)C)C=C2)=CC=C1O[Si](C)(C)C(C)(C)C | 4154.9 | Semi standard non polar | 33892256 | | Sulfasalazine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C(C)(C)C)C=C2)=CC=C1O[Si](C)(C)C(C)(C)C | 4229.9 | Standard non polar | 33892256 | | Sulfasalazine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(S(=O)(=O)N(C3=CC=CC=N3)[Si](C)(C)C(C)(C)C)C=C2)=CC=C1O[Si](C)(C)C(C)(C)C | 4783.5 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Sulfasalazine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0f6w-6695000000-47b5c3a0d5190268e477 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sulfasalazine GC-MS (2 TMS) - 70eV, Positive | splash10-00di-2549110000-cce76e754cd947c9bdf8 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sulfasalazine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Sulfasalazine , positive-QTOF | splash10-0002-0239100000-5bf223e6e250eb77105a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 10V, Positive-QTOF | splash10-0002-0009000000-9e5b613387b866753d70 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 20V, Positive-QTOF | splash10-0a4j-2019000000-5dbdcf5699c56f6a59d8 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 40V, Positive-QTOF | splash10-002b-9240000000-6268787fab73d296c1d8 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 10V, Negative-QTOF | splash10-0f6t-0009000000-5eea07137968cfa96d18 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 20V, Negative-QTOF | splash10-0udi-0009000000-642c65b2544ce824decc | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 40V, Negative-QTOF | splash10-0k97-9663000000-5acc71d633a9ef82ea98 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 10V, Positive-QTOF | splash10-001i-0009000000-a266ecec49bba90668ba | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 20V, Positive-QTOF | splash10-005a-2089000000-ad13a0c69c0256eb5505 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 40V, Positive-QTOF | splash10-0092-3936000000-d0a391d2c705ca56748e | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 10V, Negative-QTOF | splash10-0002-0009000000-cf36a51de9de200e8014 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 20V, Negative-QTOF | splash10-0002-2917000000-1f1274dcd32e5287cfb7 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sulfasalazine 40V, Negative-QTOF | splash10-0002-1900000000-16464eaa00e58b69be2d | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|